1. Home
  2. DNOW vs RARE Comparison

DNOW vs RARE Comparison

Compare DNOW & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOW Inc.

DNOW

NOW Inc.

N/A

Current Price

$15.30

Market Cap

2.9B

Sector

Industrials

ML Signal

N/A

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

N/A

Current Price

$14.84

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DNOW
RARE
Founded
1862
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.6B
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
DNOW
RARE
Price
$15.30
$14.84
Analyst Decision
Strong Buy
Buy
Analyst Count
4
20
Target Price
$18.75
★ $28.05
AVG Volume (30 Days)
1.8M
★ 5.9M
Earning Date
11-04-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.31
EPS
★ N/A
N/A
Revenue
★ $2,648,000,000.00
$673,000,000.00
Revenue This Year
$79.68
$13.37
Revenue Next Year
$7.00
$31.21
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 25.68
20.13
52 Week Low
$10.94
$12.73
52 Week High
$17.26
$39.89

Technical Indicators

Market Signals
Indicator
DNOW
RARE
Relative Strength Index (RSI) 40.72 37.44
Support Level $12.60 $13.81
Resistance Level $16.49 $16.12
Average True Range (ATR) 0.42 0.82
MACD -0.08 0.50
Stochastic Oscillator 0.87 73.45

Price Performance

Historical Comparison
DNOW
RARE

About DNOW NOW Inc.

Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: